A detailed history of Efg Asset Management (North America) Corp. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 37,129 shares of ITCI stock, worth $3.21 Million. This represents 0.46% of its overall portfolio holdings.

Number of Shares
37,129
Previous 34,452 7.77%
Holding current value
$3.21 Million
Previous $2.36 Million 15.05%
% of portfolio
0.46%
Previous 0.42%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$67.99 - $80.84 $182,009 - $216,408
2,677 Added 7.77%
37,129 $2.71 Million
Q2 2024

Jul 25, 2024

BUY
$64.76 - $79.84 $10,555 - $13,013
163 Added 0.48%
34,452 $2.36 Million
Q1 2024

May 13, 2024

BUY
$64.37 - $75.65 $124,555 - $146,382
1,935 Added 5.98%
34,289 $2.37 Million
Q4 2023

Feb 08, 2024

SELL
$46.37 - $73.65 $37,281 - $59,214
-804 Reduced 2.42%
32,354 $2.32 Million
Q3 2023

Nov 02, 2023

BUY
$52.09 - $64.1 $43,599 - $53,651
837 Added 2.59%
33,158 $1.73 Million
Q2 2023

Jul 28, 2023

SELL
$54.67 - $66.44 $104,529 - $127,033
-1,912 Reduced 5.59%
32,321 $2.05 Million
Q1 2023

Apr 27, 2023

SELL
$43.8 - $56.99 $83,964 - $109,249
-1,917 Reduced 5.3%
34,233 $1.85 Million
Q4 2022

Feb 03, 2023

SELL
$44.07 - $54.45 $53,500 - $66,102
-1,214 Reduced 3.25%
36,150 $1.91 Million
Q3 2022

Oct 28, 2022

SELL
$42.7 - $59.99 $120,029 - $168,631
-2,811 Reduced 7.0%
37,364 $1.74 Million
Q2 2022

Aug 04, 2022

BUY
$43.0 - $65.64 $62,350 - $95,178
1,450 Added 3.74%
40,175 $2.29 Million
Q1 2022

Apr 26, 2022

SELL
$38.74 - $62.09 $13,404 - $21,483
-346 Reduced 0.89%
38,725 $2.37 Million
Q4 2021

Feb 18, 2022

BUY
$35.2 - $53.42 $1.38 Million - $2.09 Million
39,071 New
39,071 $2.04 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.16B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.